IGI Logo

Caplin Point Laboratories is currently trading at Rs. 2547.30, up by 37.30 points or 1.49% from its previous closing of Rs. 2510.00 on the BSE.

The scrip opened at Rs. 2575.05 and has touched a high and low of Rs. 2589.25 and Rs. 2519.55 respectively. So far 6611 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2636.00 on 27-Dec-2024 and a 52 week low of Rs. 1221.00 on 04-Jun-2024.

Last one week high and low of the scrip stood at Rs. 2625.00 and Rs. 2469.00 respectively. The current market cap of the company is Rs. 19397.80 crore.

The promoters holding in the company stood at 70.56%, while Institutions and Non-Institutions held 5.53% and 23.91% respectively.

Caplin Point Laboratories has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for the recent inspection conducted at Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi. The unannounced USFDA inspection was conducted between August 5, 2024 and August 9, 2024 and was concluded with Zero 483 observations, reflecting the company's commitment to maintaining the highest standards of quality and compliance. The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.